Bionomics developing MS drug for Merck Serono
Submitted by art on Wed, 2008-07-02 07:08.
Not a lot of detail in this announcement, but Bionomics is developing a new generation of treatments for inflammatory disorders, based upon blockers of the Kv1.3 potassium ion channel and Merck is licensing them to treat diseases including MS. A bit more science info here.
Yet another MS drug candidate to watch out for.